Clinical Trial

A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated June 12, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single arm, open, multicenter clinical trial in which the previous treated severe hemophilia A patients receive recombinant human coagulation factor VIII for injection to evaluate the efficacy and safety of on-demand treatment in the event of new bleeding events. If evaluable surgical cases occur, the overall efficacy and safety of recombinant human coagulation factor VIII for injection as a replacement therapy for severe hemophilia A PTPs during the perioperative period will be evaluated.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-03-01.
Status change: Not Yet Recruiting → Active, Not Recruiting 2026-06-11
Trial Details
NCT Number NCT06297655
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Conditions Hemophilia A
Enrollment 60 participants
Start Date 2024-11-12
Primary Completion 2026-07 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-12